Novavax Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while ZIM Integrated Shipping Services Ltd trades at $29.26 (market cap $3.63B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 2.2× Novavax Inc's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | ZIM | |
|---|---|---|
Market Cap | $1.68B | $3.63B |
Sector | Health | Industrials |
52-Week High | $11.19 | $30.08 |
52-Week Low | $6.22 | $12.44 |
Enterprise Value | $1.26B | $7.30B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
ZIM Integrated Shipping Services trades at $30.08, up 5.25% with a bullish technical signal from moving averages. The company shows mixed fundamentals with Q2 2026 earnings beating expectations but declining profitability margins year-over-year. Valuation metrics appear attractive with P/S of 0.56 and P/B of 0.93, though analyst sentiment remains divided amid merger uncertainty with Hapag-Lloyd.
The stock faces headwinds from the uncertain $4.2 billion takeover deal and declining net income margins, but strong transpacific positioning and recent earnings beats provide upside potential. Current price sits well above the $18.25 consensus target, suggesting limited near-term upside according to Wall Street analysts.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →